Clinical Trial Update: Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial testing Exatecan Mesylate in children with relapsed or refractory rhabdomyosarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhabdomyosarcoma

Drugs mentioned

• Exatecan Mesylate (exatecan mesylate)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Sarcoma | Phase 2 | Status: COMPLETED